JRJulien Robert-Paganin

Julien Robert-Paganin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julien Robert-Paganin has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamics of the β-cardiac myosin auto-inhibited state explain cardiomyopathy pathogenesis

    by Daniel Auguin, Laurie Lannes, Carlos Kikuti, Nour Ayoub, Marie Juillé, Stéphane Réty, Neha Nandwani, Divya Pathak, Kathleen M. Ruppel, James A. Spudich, et al.

    Cardiac contractility requires precise regulation. A recently discovered form of regulation of cardiac contractility involves a β-cardiac myosin off-state, the Interacting-Heads Motif ( Car IHM). Despite its central role in cardiac physiology and disease, Car IHM structural dynamics remain poorly understood. Here, we integrate near-atomic resolution cryo-EM with all-atom molecular dynamics to characterize Car IHM in solution and in the context of the filament. We describe its conformational ensembles maintained by dynamic interfaces, and the stabilizing effect of the dilated cardiomyopathy mutation E525K, which limits S2 coiled-coil flexibility and impairs myosin activation. Intrinsically disordered regions of Car IHM and MyBP-C further modulate these dynamics. Our findings provide evidence for how Car IHM ensembles balance off/on states and anchor myosin heads in distinct thick filament environments. This integrated structural and dynamic approach enhances the understanding of thick filament regulation and facilitates predictions of the effects of genetic variants in inherited cardiomyopathies.


  • Étude structurale et fonctionnelle de la régulation de l’hélicase Prp43

    by Julien Robert-Paganin

    Les hélicases à ARN de la famille DEAH/RHA sont impliquées dans la plupart des processus essentiels à la vie tels que l'épissage, la biogenèse des ribosomes, la réplication, la transcription ou encore la détection d’ARN viraux. Ces enzymes sont capables de catalyser la dissociation de duplexes d'ARN, la réorganisation de structures secondaires ou de remodeler des complexes ARN-protéines. L'hélicase DEAH/RHA Prp43 présente la particularité d'être bifonctionnelle. Prp43 est impliquée dans l'épissage des Pré-ARNm, où elle assure le recyclage du spliceosome et du lasso, mais aussi dans la biogenèse des ribosomes où elle est impliquée dans la maturation des deux sous-unités. Prp43 est activée et régulée par cinq partenaires protéiques : Ntr1, Gno1, Pfa1, RBM5 et GPATCH2. Ces partenaires protéiques présentent tous un domaine G-patch et sont capables de stimuler les activités hélicase et ATPase de Prp43. La structure cristallographique de Prp43 en complexe avec l'ADP a été résolue au laboratoire. Cette structure a mis en évidence un mode de fixation du nucléotide inédit chez les autres hélicases, notamment au niveau de la base qui s'empile entre la phénylalanine 357 (F357) du domaine RecA2 et l'arginine 159 (R159) du domaine RecA1. Les déterminants de l'activation de Prp43 par les protéines à domaine G-patch demeurent méconnus. Dans ce travail, nous avons cherché à déterminer quel était le rôle de l’empilement de la base dans l’activation de Prp43. Nous présentons ici plusieurs structures cristallographiques de Prp43 en complexe avec tous les nucléotides diphosphates(NDP) et les désoxynucléotides triphosphates (dNDP). Ces structures ont permis de conclure qu'il y avait des différences dans l’empilement de la base selon le (d)NDP considéré. Des dosages d'activité NTPase de Prp43 avec et sans son partenaire protéique Pfa1 montrent que lorsque la base ne s'empile pas avec la F357 et la R159, l'activité de l'enzyme n'est pas correctement régulée par son partenaire protéique. Les dosages d’activité enzymatique sur les mutants ponctuels F357A et R159A révèlent que le résidu F357 permet de moduler l’activité de Prp43. Tous ces résultats nous ont permis de mettre en évidence un modèle de la régulation de Prp43 par les protéines à domaines G-patch et d'expliquer l'importance du mode de fixation de la base à l'enzyme dans cette régulation.

  • Open Access

    Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy

    by James A Spudich, Neha Nandwani, Julien Robert-Paganin, Anne Houdusse, Kathleen M Ruppel

    Human β-cardiac myosin exists in an ON-state where both myosin heads are accessible for interaction with actin, and an OFF-state where the heads are folded back onto their own coiled-coil tail, interacting with each other via an interacting-heads motif (IHM). Hypertrophic cardiomyopathy (HCM) mutations in β-cardiac myosin cause hypercontractility of the heart. Nine years ago, a unifying hypothesis proposed that hypercontractility caused by myosin HCM-associated mutations is primarily due to an increase in the number of ON-state myosin molecules, rather than altered fundamental alterations of functional myosin parameters such as intrinsic motor force, its velocity of movement along actin, or its ATPase turnover rate, all of which impact power output. We here revisit this unifying hypothesis in light of accumulated data measuring all these parameters, and the recent availability of a 3.6 Å-resolution structure of the human β-cardiac myosin IHM. Biochemical measurements show that nearly all myosin HCM mutations examined exhibit more ON-state myosin regardless of where they occur in the myosin head domain, consistent with the unifying hypothesis.


  • Top Cited Papers
    Open Access

    Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy

    by James J. Hartman, Darren T. Hwee, Julien Robert-Paganin, Chihyuan Chuang, Eva R. Chin, Samantha Edell, Ken H. Lee, Roshni Madhvani, Preeti Paliwal, Julien Pernier, et al.

    Hypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly slowing phosphate release, stabilizing a weak actin-binding state. Binding to an allosteric site on the myosin catalytic domain distinct from mavacamten, aficamten prevents the conformational changes necessary to enter the strongly actin-bound force-generating state. In doing so, aficamten reduces the number of functional myosin heads driving sarcomere shortening. The crystal structure of aficamten bound to cardiac myosin in the pre-powerstroke state provides a basis for understanding its selectivity over smooth and fast skeletal muscle. Furthermore, in cardiac myocytes and in mice bearing the hypertrophic R403Q cardiac myosin mutation, aficamten reduces cardiac contractility. Our findings suggest aficamten holds promise as a therapy for HCM.


  • Top Cited Papers
    Open Access

    Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

    by Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse

    Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Omecamtiv mecarbil and Mavacamten are two such molecules that completed phase 3 clinical trials, and the inhibitor Mavacamten is now approved by the FDA. In contrast to Mavacamten, Omecamtiv mecarbil acts as an activator of cardiac contractility. Here, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All-atom molecular dynamics simulations reveal how these molecules produce distinct effects in motor allostery thus impacting force production in opposite way. Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.


  • Open Access

    Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design

    by Dihia Moussaoui, James P. Robblee, Julien Robert-Paganin, Daniel Auguin, Fabio Fisher, Patricia M. Fagnant, Jill E. Macfarlane, Julia Schaletzky, Eddie Wehri, Christoph Mueller-Dieckmann, et al.

    Malaria results in more than 500,000 deaths per year and the causative Plasmodium parasites continue to develop resistance to all known agents, including different antimalarial combinations. The class XIV myosin motor PfMyoA is part of a core macromolecular complex called the glideosome, essential for Plasmodium parasite mobility and therefore an attractive drug target. Here, we characterize the interaction of a small molecule (KNX-002) with PfMyoA. KNX-002 inhibits PfMyoA ATPase activity in vitro and blocks asexual blood stage growth of merozoites, one of three motile Plasmodium life-cycle stages. Combining biochemical assays and X-ray crystallography, we demonstrate that KNX-002 inhibits PfMyoA using a previously undescribed binding mode, sequestering it in a post-rigor state detached from actin. KNX-002 binding prevents efficient ATP hydrolysis and priming of the lever arm, thus inhibiting motor activity. This small-molecule inhibitor of PfMyoA paves the way for the development of alternative antimalarial treatments.


  • Open Access

    Cryo-EM structure of the folded-back state of human β-cardiac myosin

    by Alessandro Grinzato, Daniel Auguin, Carlos Kikuti, Neha Nandwani, Dihia Moussaoui, Divya Pathak, Eaazhisai Kandiah, Kathleen M. Ruppel, James A. Spudich, Anne Houdusse, et al.

    To save energy and precisely regulate cardiac contractility, cardiac muscle myosin heads are sequestered in an ‘off’ state that can be converted to an ‘on’ state when exertion is increased. The ‘off’ state is equated with a folded-back structure known as the interacting-heads motif (IHM), which is a regulatory feature of all class-2 muscle and non-muscle myosins. We report here the human β-cardiac myosin IHM structure determined by cryo-electron microscopy to 3.6 Å resolution, providing details of all the interfaces stabilizing the ‘off’ state. The structure shows that these interfaces are hot spots of hypertrophic cardiomyopathy mutations that are thought to cause hypercontractility by destabilizing the ‘off’ state. Importantly, the cardiac and smooth muscle myosin IHM structures dramatically differ, providing structural evidence for the divergent physiological regulation of these muscle types. The cardiac IHM structure will facilitate development of clinically useful new molecules that modulate IHM stability.


  • Open Access

    Cryo-EM structure of the folded-back state of human β-cardiac myosin*

    by Alessandro Grinzato, Daniel Auguin, Carlos Kikuti, Neha Nandwani, Dihia Moussaoui, Divya Pathak, Eaazhisai Kandiah, Kathleen M. Ruppel, James A. Spudich, Anne Houdusse, et al.

    Summary: During normal levels of exertion, many cardiac muscle myosin heads are sequestered in an off-state even during systolic contraction to save energy and for precise regulation. They can be converted to an on-state when exertion is increased. Hypercontractility caused by hypertrophic cardiomyopathy (HCM) myosin mutations is often the result of shifting the equilibrium toward more heads in the on-state. The off-state is equated with a folded-back structure known as the interacting head motif (IHM), which is a regulatory feature of all muscle myosins and class-2 non-muscle myosins. We report here the human β-cardiac myosin IHM structure to 3.6 Å resolution. The structure shows that the interfaces are hot spots of HCM mutations and reveals details of the significant interactions. Importantly, the structures of cardiac and smooth muscle myosin IHMs are dramatically different. This challenges the concept that the IHM structure is conserved in all muscle types and opens new perspectives in the understanding of muscle physiology. The cardiac IHM structure has been the missing puzzle piece to fully understand the development of inherited cardiomyopathies. This work will pave the way for the development of new molecules able to stabilize or destabilize the IHM in a personalized medicine approach. *This manuscript was submitted to Nature Communications in August 2022 and dealt efficiently by the editors. All reviewers received this version of the manuscript before 9 208 August 2022. They also received coordinates and maps of our high resolution structure on the 18 208 August 2022. Due to slowness of at least one reviewer, this contribution was delayed for acceptance by Nature Communications and we are now depositing in bioRxiv the originally submitted version written in July 2022 for everyone to see. Indeed, two bioRxiv contributions at lower resolution but adding similar concepts on thick filament regulation were deposited this week in bioRxiv, one of the contributions having had access to our coordinates. We hope that our data at high resolution will be helpful for all readers that appreciate that high resolution information is required to build accurate atomic models and discuss implications for sarcomere regulation and the effects of cardiomyopathy mutations on heart muscle function.


  • Open Access

    Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design

    by Dihia Moussaoui, James P. Robblee, Daniel Auguin, Fabio Fisher, Patricia M. Fagnant, Jill E. Macfarlane, Julia Schaletzky, Eddie Wehri, Christoph Mueller-Dieckmann, Jake Baum, et al.

    Malaria is responsible for more than a half million deaths per year. The Plasmodium parasites responsible continue to develop resistance to all known agents, despite treatment with different antimalarial combinations. The atypical Myosin A motor (PfMyoA) is part of a core macromolecular complex called the glideosome, essential for Plasmodium parasite mobility and therefore an attractive drug target. Here, we characterize the interaction of a small molecule (KNX-002) with PfMyoA. KNX-002 inhibits PfMyoA ATPase activity in vitro and blocks asexual blood stage growth of merozoites, one of three motile Plasmodium life-cycle stages. Combining biochemical assays, X-ray crystallography and molecular dynamics, we demonstrate that KNX-002 targets a novel pocket in PfMyoA, sequestering it in a post-rigor state detached from actin. KNX-002 binding affects Mg 2+ coordination near ATP, preventing ATP hydrolysis and thus inhibiting motor activity. This first-in-class small-molecule inhibitor of PfMyoA paves the way for developing a new generation of antimalarial treatments.


  • Open Access

    A Perspective for Ménière’s Disease: In Silico Investigations of Dexamethasone as a Direct Modulator of AQP2

    by Robin Mom, Julien Robert-Paganin, Thierry Mom, Christian Chabbert, Stéphane Réty, Daniel Auguin

    Ménière’s disease is a chronic illness characterized by intermittent episodes of vertigo associated with fluctuating sensorineural hearing loss, tinnitus and aural pressure. This pathology strongly correlates with a dilatation of the fluid compartment of the endolymph, so-called hydrops. Dexamethasone is one of the therapeutic approaches recommended when conventional antivertigo treatments have failed. Several mechanisms of actions have been hypothesized for the mode of action of dexamethasone, such as the anti-inflammatory effect or as a regulator of inner ear water homeostasis. However, none of them have been experimentally confirmed so far. Aquaporins (AQPs) are transmembrane water channels and are hence central in the regulation of transcellular water fluxes. In the present study, we investigated the hypothesis that dexamethasone could impact water fluxes in the inner ear by targeting AQP2. We addressed this question through molecular dynamics simulations approaches and managed to demonstrate a direct interaction between AQP2 and dexamethasone and its significant impact on the channel water permeability. Through compartmentalization of sodium and potassium ions, a significant effect of Na+ upon AQP2 water permeability was highlighted as well. The molecular mechanisms involved in dexamethasone binding and in its regulatory action upon AQP2 function are described.